BioLineRx (NASDAQ:BLRX – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
1.6% of BioLineRx shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Volatility & Risk
BioLineRx has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for BioLineRx and Nurix Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLineRx | 1 | 0 | 0 | 0 | 1.00 |
| Nurix Therapeutics | 1 | 0 | 14 | 0 | 2.87 |
Nurix Therapeutics has a consensus target price of $34.43, indicating a potential upside of 116.80%. Given Nurix Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than BioLineRx.
Profitability
This table compares BioLineRx and Nurix Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLineRx | -502.08% | -34.80% | -18.27% |
| Nurix Therapeutics | 42.01% | 49.34% | 38.61% |
Earnings & Valuation
This table compares BioLineRx and Nurix Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioLineRx | $1.18 million | 6.31 | -$1.17 million | ($1.69) | -0.88 |
| Nurix Therapeutics | $83.98 million | 20.66 | -$264.46 million | $2.31 | 6.87 |
BioLineRx has higher earnings, but lower revenue than Nurix Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Nurix Therapeutics beats BioLineRx on 12 of the 14 factors compared between the two stocks.
About BioLineRx
BioLineRx Ltd. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious medical conditions. The company is headquartered in Modi’in, Israel, and is listed on the Nasdaq Capital Market under the symbol BLRX. BioLineRx’s primary product is APHEXDA (motixafortide), a CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in combination with filgrastim to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma.
About Nurix Therapeutics
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down.
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
